Company: BDRX
Filing Date: 2025-05-12
Form Type: 424B3
Source: 0001214659-25-007342
Chunk: 116

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-05-12
Form: 424B3
Chunk 116
---
 prices and at terms
then prevailing or at prices related to the then current market price. Each such registered broker-dealer will be an underwriter within
the meaning of Section 2(a)(11) of the Securities Act. The Selling Shareholder has informed us that each such broker-dealer will receive
commissions from the Selling Shareholder that will not exceed customary brokerage commissions.

Brokers, dealers, underwriters
or agents participating in the distribution of our Depositary Shares offered by this prospectus may receive compensation in the form of
commissions, discounts, or concessions from the purchasers, for whom the broker-dealers may act as agent, of the shares sold by the Selling
Shareholder through this prospectus. The compensation paid to any such particular broker-dealer by any such purchasers of our Depositary
Shares sold by the Selling Shareholder may be less than or in excess of customary commissions. Neither we nor the Selling Shareholder
can presently estimate the amount of compensation that any agent will receive from any purchasers of our common stock sold by the Selling
Shareholder.

We know of no existing arrangements
between the Selling Shareholder or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution of
our Depositary Shares offered by this prospectus.

We may from time to time file
with the SEC one or more supplements to this prospectus or amendments to the registration statement of which this prospectus forms a part
to amend, supplement or update information contained in this prospectus, including, if and when required under the Securities Act, to
disclose certain information relating to a particular sale of shares offered by this prospectus by the Selling Shareholder, including
the names of any brokers, dealers, underwriters or agents participating in the distribution of such shares by the Selling Shareholder,
any compensation paid by the Selling Shareholder to any such brokers, dealers, underwriters or agents, and any other required information.

We will pay the expenses incident
to the registration under the Securities Act of the offer and sale of our Depositary Shares covered by this prospectus by the Selling
Shareholder. As consideration for its irrevocable commitment to purchase our Depositary Shares under the Purchase Agreement, we have agreed
to issue to the Selling Shareholder 2.5% of the Commitment Amount in Depositary Shares, with 1.75% of such shares paid up front and the
balance pro-rated with each Fixed Purchase, VWAP Purchase or Additional VWAP Purchase, as